ATE252091T1 - Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren - Google Patents

Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren

Info

Publication number
ATE252091T1
ATE252091T1 AT00959401T AT00959401T ATE252091T1 AT E252091 T1 ATE252091 T1 AT E252091T1 AT 00959401 T AT00959401 T AT 00959401T AT 00959401 T AT00959401 T AT 00959401T AT E252091 T1 ATE252091 T1 AT E252091T1
Authority
AT
Austria
Prior art keywords
ppars
zol
biaryl
thia
oxa
Prior art date
Application number
AT00959401T
Other languages
English (en)
Inventor
Dawn A Brooks
Christopher J Rito
Anthony J Shuker
Samuel J Dominianni
Alan M Warshawsky
Lynn S Gossett
Donald P Matthews
David A Hay
Robert J Ardecky
Pierre-Yves Michellys
John S Tyhonas
Original Assignee
Lilly Co Eli
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Ligand Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE252091T1 publication Critical patent/ATE252091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00959401T 1999-08-27 2000-08-23 Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren ATE252091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15116299P 1999-08-27 1999-08-27
PCT/US2000/023358 WO2001016120A1 (en) 1999-08-27 2000-08-23 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Publications (1)

Publication Number Publication Date
ATE252091T1 true ATE252091T1 (de) 2003-11-15

Family

ID=22537578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959401T ATE252091T1 (de) 1999-08-27 2000-08-23 Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren

Country Status (13)

Country Link
US (3) US6417212B1 (de)
EP (1) EP1206457B1 (de)
JP (1) JP2003508389A (de)
AR (1) AR025386A1 (de)
AT (1) ATE252091T1 (de)
AU (1) AU7073400A (de)
CA (1) CA2382966A1 (de)
DE (1) DE60005973T2 (de)
DK (1) DK1206457T3 (de)
ES (1) ES2204684T3 (de)
PE (1) PE20010529A1 (de)
PT (1) PT1206457E (de)
WO (1) WO2001016120A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
EP1305017A4 (de) * 2000-08-02 2004-01-14 Pharmanutrients Verfahren und zusammensetzung zur vorbeugung und behandlung von syndrom x
EP1310494B1 (de) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. Ppar-delta aktivatoren
EP1313716B1 (de) 2000-08-23 2007-05-02 Eli Lilly And Company Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
WO2002018355A1 (en) * 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
JP2004506722A (ja) * 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体の調節方法
GB0029974D0 (en) 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CZ301871B6 (cs) 2001-01-26 2010-07-14 Schering Corporation Kombinace aktivátoru receptoru, aktivovaného proliferátorem peroxisomu fenofibrátu s inhibitorem vstrebávání sterolu ezetimibem pro použití pri cévních chorobách
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
EA200400010A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов активаторов пролиферации пероксисом
HRP20031002A2 (en) * 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
BRPI0211844B8 (pt) 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EA007163B1 (ru) * 2001-11-30 2006-08-25 Эли Лилли Энд Компани Агонисты рецепторов, активируемых пероксисомным пролифератором
AU2003214932A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2003091211A1 (ja) * 2002-03-28 2005-09-02 住友製薬株式会社 新規ヘテロアリール化合物
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JP2005529975A (ja) 2002-06-19 2005-10-06 イーライ・リリー・アンド・カンパニー アミドリンカーペルオキシソーム増殖因子活性化受容体調節因子
JP2006508189A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004063165A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company A pyrazole derivative as ppar modulator
AU2004207444B2 (en) * 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
DE602004010889T2 (de) 2003-02-14 2008-12-11 Eli Lilly And Co., Indianapolis Sulfonamid-derivate als ppar-modulatoren
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004080943A1 (ja) * 2003-03-11 2004-09-23 Ono Pharmaceutical Co., Ltd. シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
CA2539554A1 (en) * 2003-09-22 2005-03-31 Ono Pharmaceutical Co., Ltd. Phenylacetic acid derivative, process for producing the same, and use
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
WO2005095364A1 (ja) * 2004-03-30 2005-10-13 Daiichi Pharmaceutical Co. Ltd. フェノキシ酢酸誘導体及びそれを用いた医薬
RU2384573C2 (ru) 2004-04-28 2010-03-20 Ф. Хоффманн-Ля Рош Аг Пиразол- и фенилпроизводные в качестве ингибиторов ppar
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CA2567437A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
MX2007001942A (es) 2004-08-17 2007-05-09 Galderma Res & Dev Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
FR2874379B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20070042553A (ko) * 2004-08-17 2007-04-23 갈데르마 리써어치 앤드 디벨로프먼트 Ｐｐａｒ 유형의 수용체를 활성화시키는 신규 이방향족화합물 및 화장용 또는 약학 조성물에서의 그의 용도
FR2874378B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007052023A2 (en) * 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
JP2009519308A (ja) * 2005-12-15 2009-05-14 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
US8023825B2 (en) * 2006-04-04 2011-09-20 Cisco Technology, Inc. Optical switching architectures for nodes in WDM mesh and ring networks
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
KR101130380B1 (ko) * 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2277874B1 (de) 2008-04-15 2018-06-27 Nippon Chemiphar Co., Ltd. Aktivator für peroxisom-proliferator-aktivierte rezeptoren
US20100216827A1 (en) * 2008-10-21 2010-08-26 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SG10201913609PA (en) 2014-12-23 2020-03-30 4D Pharma Res Ltd Immune modulation
SI3193901T1 (en) 2014-12-23 2018-06-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
MX2017016529A (es) 2015-06-15 2018-03-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
JP6426265B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2766867T3 (es) 2015-06-15 2020-06-15 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3209310T3 (pl) 2015-11-20 2018-08-31 4D Pharma Research Limited Kompozycja zawierająca szczepy bakteryjne
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EA035949B1 (ru) 2016-03-04 2020-09-04 4Д ФАРМА ПиЭлСи Применение композиции, содержащей бактериальный штамм вида blautia hydrogenotrophica, и способ лечения или предотвращения висцеральной гиперчувствительности
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
HRP20210205T1 (hr) 2017-06-14 2021-03-19 4D Pharma Research Limited Sastavi koji sadrže bakterijske sojeve
EP3638271B1 (de) 2017-06-14 2020-10-14 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
BR112019026667A2 (pt) 2017-06-14 2020-06-23 4D Pharma Research Limited Composições que compreendem uma cepa bacteriana do gênero megasphaera e usos das mesmas
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1993021166A1 (en) * 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
EP0648212B1 (de) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US6068976A (en) 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH08325264A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
ES2202582T3 (es) * 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
NZ334738A (en) 1996-08-19 2001-01-26 Japan Tobacco Inc Pyridinyl or oxazolyl substituted phenyl-propionic acid derivatives
EP1005344A4 (de) * 1996-12-31 2003-03-19 Salk Inst For Biological Studi Behandlung von liposarcomas mit einer kombination aus thiazolidinedions und selektiven retinoid-x-rezeptor agonisten
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
ATE352561T1 (de) * 1997-05-30 2007-02-15 Dana Farber Cancer Inst Inc Pgc-1, ein neuartiger ppar-gamma-koaktivator aus braunem fettgewebe
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US7098025B1 (en) * 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
CA2306825A1 (en) * 1997-10-17 1999-04-29 Avantis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
WO1999032465A1 (en) * 1997-12-19 1999-07-01 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1051403A1 (de) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Alkansaüren und deren verwendung in heilmittel, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
GB2335597A (en) 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
AU3333399A (en) * 1998-04-06 1999-10-25 Janssen Pharmaceutica N.V. Nucleotide sequence expressing human fatty acid transport protein and corresponding aminoacid sequence. use for the regulation of fatty acids metabolism
WO1999058510A1 (en) * 1998-05-11 1999-11-18 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2003508389A (ja) 2003-03-04
US20040019090A1 (en) 2004-01-29
EP1206457B1 (de) 2003-10-15
DK1206457T3 (da) 2004-02-16
AR025386A1 (es) 2002-11-27
AU7073400A (en) 2001-03-26
DE60005973D1 (de) 2003-11-20
EP1206457A1 (de) 2002-05-22
DE60005973T2 (de) 2004-05-13
CA2382966A1 (en) 2001-03-08
PT1206457E (pt) 2004-03-31
US6417212B1 (en) 2002-07-09
US20030045558A1 (en) 2003-03-06
WO2001016120A9 (en) 2002-07-11
ES2204684T3 (es) 2004-05-01
PE20010529A1 (es) 2001-05-18
WO2001016120A1 (en) 2001-03-08
US6825222B2 (en) 2004-11-30
US6610696B2 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
ATE252091T1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60006580D1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE60010333D1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
DE60020701D1 (de) Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATA5422000A (de) Oximderivate und ihre verwendung als latente säuren
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE60041343D1 (de) Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DE59710580D1 (de) Thiocyano-triazolyl-derivate und ihre verwendung als mikrobizide
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
DE60004658D1 (de) Thiazolidindionderivat und seine verwendung als antidiabetikum
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
DE69902387D1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
ATE247109T1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE60009911D1 (de) Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
ATE316087T1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206457

Country of ref document: EP

REN Ceased due to non-payment of the annual fee